Clinical Trials Logo

Esophageal Carcinoma clinical trials

View clinical trials related to Esophageal Carcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03220009 Withdrawn - Recurrent Melanoma Clinical Trials

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Start date: November 3, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well nivolumab or expectant observation following ipilimumab, nivolumab, and surgery work in treating patients with high-risk mucosal melanoma that is restricted to the site of origin without evidence of spread, has spread to a local and regional area of the body, or has come back. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Sometimes the mucosal melanoma may not need more treatment until it progresses. In this case, observation may be sufficient. It is not known if nivolumab or expectant observation following ipilimumab, nivolumab, and surgery may be better in treating patients with mucosal melanoma.

NCT ID: NCT00636298 Withdrawn - Clinical trials for Esophageal Carcinoma

Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the drug bevacizumab in combination with cetuximab. Because this combination has not been tested in cancer patients before, results will be analyzed to see what effects the combination of bevacizumab with cetuximab has on esophageal cancer.